<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832882</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2016-2244</org_study_id>
    <nct_id>NCT02832882</nct_id>
  </id_info>
  <brief_title>RFA for Small HCC With No-touch Technique Using Octopus Electrode</brief_title>
  <official_title>Radiofrequency Ablation for Small Hepatocellular Carcinoma Using Octopus Electrode and No-touch Technique: Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators are going to prospectively compare the clinical outcomes
      (technical success rate, 12 month local tumor progression rate, complication rate, tumor
      seeding rate) of Radiofrequency ablation (RFA) with octopus electrode and no-touch technique
      for Hepatocellular carcinoma (HCC) to those of RFA with conventional tumor puncture method
      with the same device.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 month local tumor progression (LTP) rate</measure>
    <time_frame>12 month after RFA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor seeding rate</measure>
    <time_frame>12 months after RFA</time_frame>
    <description>incidence of tract seeding after RFA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate related with RFA</measure>
    <time_frame>1 month</time_frame>
    <description>RFA-related complication rate such as death, abscess, bleeding..etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>1 months</time_frame>
    <description>presence or absence of residual lesion on follow-up imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ablation time</measure>
    <time_frame>3 days after RFA</time_frame>
    <description>ablation time for tumor ablation</description>
  </other_outcome>
  <other_outcome>
    <measure>Intrahepatic distant mets</measure>
    <time_frame>12 months after RFA</time_frame>
    <description>incidence of intrahepatic distant metastasis after RFA</description>
  </other_outcome>
  <other_outcome>
    <measure>Extrahepatic distant mets</measure>
    <time_frame>12 months after RFA</time_frame>
    <description>incidence of extrahepatic distant metastasis after RFA</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical efficacy 1</measure>
    <time_frame>2 days after RFA</time_frame>
    <description>Assessment of ablative margin using score 1-4 (1: residual tumor; 4: equal to or larger than 5mm) in side-by-side comparison of pre-RFA CT/MR and post-RFA CT using visual assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical efficacy 2</measure>
    <time_frame>2 days after RFA</time_frame>
    <description>Assessment of ablative margin using score 1-4 (1: residual tumor; 4: equal to or larger than 5mm) in side-by-side comparison of pre-RFA CT/MR and post-RFA CT using registration software</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>No-touch RFA arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional tumor puncture RFA arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No-touch RFA</intervention_name>
    <description>No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.</description>
    <arm_group_label>No-touch RFA arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional tumor puncture RFA</intervention_name>
    <description>Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.</description>
    <arm_group_label>Conventional tumor puncture RFA arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child-Pugh class A

          -  patient with 1cm-2.5cm sized HCC

          -  1 or 2 HCCs

          -  being referred for curative purpose of RFA

          -  sign informed consent

        Exclusion Criteria:

          -  maximum tumor diameter greater than 2.5cm

          -  Child-Pugh class B or C

          -  more than 3 HCC lesions

          -  invisible tumor even after US/CT or US/MR fusion

          -  presence of vascular tumor thrombosis or extrahepatic metastasis

          -  severe coagulopathy (PLT &lt; 50K, PT &lt; 50% of normal range)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Hee Lee, RN</last_name>
    <phone>82-2-2072-4177</phone>
    <email>redlion55@naver.com</email>
  </overall_contact>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>RFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

